FDA-cleared profile

AI Segmentation

Varian Medical Systems, Inc. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: AI Segmentation version 2.0 is a cloud web application that generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review, editing, and approval in Eclipse treatment-planning workflows; it does not provide clinical decisions or evaluate treatment plans.

Clinical role
Static cloud-based deep-learning and classical organ-at-risk contour generation with web review and simple editing.
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Keep in mind: The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AI Segmentation version 2.0 is a cloud web application that generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review, editing, and approval in Eclipse treatment-planning workflows; it does not provide clinical decisions or evaluate treatment plans.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Multi-region Input: CT images for use in radiation therapy treatment planning.
  • Who uses it?Intended users: Qualified expert radiation-therapy treatment planners and approving physicians.
  • What does the software produce?Output: Reviewed organ-at-risk contours selected for export into Eclipse Treatment Planning System.
  • What is its most important limitation?Key limitation: The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.

Clinical takeaway. Clinical role: AI Segmentation version 2.0 is a cloud web application that generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review, editing, and approval in Eclipse treatment-planning workflows; it does not provide clinical decisions or evaluate treatment plans.

Evidence takeaway. Evidence from the reviewed source record: K211881 reports software verification and model-level Dice comparison against ground truth, literature values, or the prior model. Clinical experts also used a qualitative target of 80% of scores rating contours acceptable with minor or no adjustment; no sample sizes or organ-level results are disclosed.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AI Segmentation version 2.0 is a cloud web application that generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review, editing, and approval in Eclipse treatment-planning workflows; it does not provide clinical decisions or evaluate treatment plans.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Static cloud-based deep-learning and classical organ-at-risk contour generation with web review and simple editing.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
CT images for use in radiation therapy treatment planning.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet states CT images but does not state DICOM in this submission text.

Output and clinician action
Reviewed organ-at-risk contours selected for export into Eclipse Treatment Planning System.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Radiation-oncology planning departments using compatible Eclipse workflows.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified expert radiation-therapy treatment planners and approving physicians.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
K211881 reports software verification and model-level Dice comparison against ground truth, literature values, or the prior model. Clinical experts also used a qualitative target of 80% of scores rating contours acceptable with minor or no adjustment; no sample sizes or organ-level results are disclosed.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K211881 reports software verification and model-level Dice comparison against ground truth, literature values, or the prior model. Clinical experts also used a qualitative target of 80% of scores rating contours acceptable with minor or no adjustment; no sample sizes or organ-level results are disclosed.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Expert acceptability target

80 %

  • EndpointScores rated acceptable with minor or no adjustments
  • PopulationAI Segmentation
  • Tested versionVarian AI Segmentation version 2.0

K211881 FDA performance package for AI Segmentation

  • DesignManufacturer nonclinical algorithm verification using Dice and expert qualitative acceptability scoring
  • PopulationCT organ-at-risk structures across head and neck, thorax, abdomen, and pelvis
  • Scopeexact submission
  • Tested versionVarian AI Segmentation version 2.0
  • IndependenceSponsor or vendor study

K211881

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K211881 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: CT images for use in radiation therapy treatment planning.

    Scope: Exact FDA submission. The exact packet states CT images but does not state DICOM in this submission text.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K211881: AI Segmentation

  2. Routing

    Source context, not route validation: Cloud web application integrated with Eclipse for contour export; validate DICOM routing, structure naming, image association, browser and identity controls, editing, approval, and downtime procedures.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K211881: AI Segmentation

  3. AI processing

    Source context, not route validation: Software-only cloud application with a web interface and Eclipse integration; exact hosting, tenancy, region, identity, audit, and support architecture require vendor confirmation.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K211881: AI Segmentation

  4. Returned objects

    Source context, not route validation: Reviewed organ-at-risk contours selected for export into Eclipse Treatment Planning System.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K211881: AI Segmentation

  5. Viewer/worklist/report

    Unresolved route: Reviewed organ-at-risk contours selected for export into Eclipse Treatment Planning System.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K211881: AI Segmentation

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software-only cloud application with a web interface and Eclipse integration; exact hosting, tenancy, region, identity, audit, and support architecture require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Cloud web application integrated with Eclipse for contour export; validate DICOM routing, structure naming, image association, browser and identity controls, editing, approval, and downtime procedures.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own press release (/press/releases/varian-closing) states it completed the acquisition of Varian Medical Systems, Inc. Corporate program statement; exact-release scope is not established.

Training
Only qualified expert radiation-therapy treatment planners and approving physicians. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K211881 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Cloud web application integrated with Eclipse for contour export; validate DICOM routing, structure naming, image association, browser and identity controls, editing, approval, and downtime procedures.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211881
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-09-02
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
20Screened PubMed leads
5Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 5 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 5 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA K211881: AI Segmentation

    U.S. Food and Drug Administration - Published 2021-09-02 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, output, limitations, input, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K211881 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K232928

DeepContour (V1.0)

Wisdom Technologies., Inc.

Authorized purpose: DeepContour uses deep-learning CT processing to generate editable organ contours and RTSTRUCT objects for selected adult radiation-treatment planning workflows, with quantitative statistics, registration, and three-dimensional visualization; it does not contour tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2024-05-07
FDA-cleared K230082

Auto Segmentation

GE Medical Systems, LLC

Authorized purpose: Auto Segmentation generates initial DICOM RT Structure Set contours for 40 organs or subregions from adult contrast or noncontrast CT across head and neck, thorax, abdomen, and pelvis; qualified radiotherapy staff must review labels and edit contours before planning.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2023-05-04
FDA-cleared K222312

RayStation 12A

RaySearch Laboratories AB (publ)

Authorized purpose: RayStation 12A is configurable software for radiation therapy and medical oncology that proposes treatment plans from user input. Authorized users may use reviewed and approved plans to support treatment administration; the system includes image handling, contouring, treatment planning and optimization, dose calculation and evaluation, machine commissioning, treatment interfaces, and machine-learning segmentation or planning functions.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2023-03-29
FDA-cleared K203469

AI Segmentation

Varian Medical Systems, Inc.

Authorized purpose: AI Segmentation version 1.0 is a static, cloud-hosted web application that generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review and approval in Eclipse treatment-planning workflows; this release does not include manual editing tools.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2021-04-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history